Advertisement
News

Study examines impact of chronic conditions on outcomes for pediatric patients with RSV admitted to ICU

Make CHEST Physician® a trusted source
Taylor L. Olson, MD
Taylor L. Olson, MD

Most research and prevention strategies for respiratory syncytial virus (RSV) have focused on the youngest children and older adults, but a recent study indicates that some older children and adolescents may benefit from expanded prevention efforts. The study found that children ages 2 to 17 years with complex chronic conditions face increased odds of RSV-related complications and death.1

Lead author Taylor L. Olson, MD, a specialist in pediatric critical care medicine at Children’s National Hospital in Washington, DC, said earlier research that her group conducted on pediatric ICU resource use showed a surprising proportion of RSV-related ICU admissions among children 2 years old and older.

Most RSV literature in pediatric patients focuses on infants and children younger than 2 years of age, so her group wanted to explore this underrecognized population of older pediatric patients, Dr. Olson said. The new data could expand the groups of pediatric patients recommended for RSV prevention measures.

“We’re in an era of rapidly evolving prevention strategies that we didn’t have to the same degree a decade ago,” she said. “So it’s important to understand which populations are experiencing the greatest burden of not only hospitalization and medical encounters but also severe outcomes and death. Even though severe outcomes may not be common on the whole, they are still important to potentially prevent.”

This retrospective multicenter cohort study included 6,430 patients aged 2 to 17 years who were admitted to the ICU with RSV, identified by laboratory testing or diagnosis codes. The primary outcome, hospital mortality, occurred in 484 admissions (7.5%). When looking at all RSV-associated ICU admissions from birth age to 17 years old, the cohort including those age 2 to 17 years accounted for 65.9% of all deaths.

Results also showed that mortality in that cohort was concentrated in those patients with complex chronic conditions, with 93.8% of all deaths occurring in patients with at least one complex chronic condition. Furthermore, increasing complex chronic condition burden was strongly associated with mortality, particularly among patients with three or more complex chronic conditions (MOR, 22.56; 95% CI, 15.44-32.97). This association persisted across age strata, highlighting the substantial contribution of underlying chronic disease burden to mortality among children hospitalized in the ICU with RSV infections.

“Mortality was concentrated in the medically complex patients, but severe disease and ICU admission were not limited exclusively to those patients,” Dr. Olson said. “We did see in ICU admissions of children aged 2 to 5 years [that] half had no condition identified. So it’s not entirely about medically complex patients. There are still severe disease and ICU needs occurring in children aged 2 to 5 years, even without a comorbid condition.”

Study limitations included possible inaccuracies and variability in diagnosis and coding. Dr. Olson also said the research team could not determine to what degree RSV or complex chronic conditions contributed to disease or death, account for all confounders, or adjust for illness severity at the time of ICU admission.

“We’ve highlighted the fact that certain populations of older children and adolescents may warrant further study with respect to expanding preventive strategies,” Dr. Olson said. “Our study was not designed to evaluate whether outcomes would change if prevention was expanded, however, so additional studies are needed.”


References

1. Olson TL, Trujillo Rivera EA, Patel AK, Mejias A, Pollack MM. Respiratory syncytial virus-associated disease in children receiving intensive care. JAMA Netw Open. 2026;9(9):e2634138. doi:10.1001/jamanetworkopen.2026.34138